Does taltz cause ibd?

What is the reported connection between Taltz and IBD?

Taltz (ixekizumab) is an interleukin-17A inhibitor used for psoriasis, psoriatic arthritis, and ankylosing spondylitis. Clinical-trial data and post-marketing reports have documented new-onset or worsening inflammatory bowel disease in a small percentage of patients. The prescribing information lists IBD (Crohn’s disease and ulcerative colitis) as an adverse reaction that requires monitoring.

Who is most likely to develop IBD while taking Taltz?

Patients with a personal or family history of IBD appear to carry higher risk. In pooled phase-3 studies, the incidence of IBD was roughly 0.2–0.4 events per 100 patient-years, but rates rose among those with prior gastrointestinal inflammation. Baseline colonoscopy or referral to gastroenterology is sometimes advised before starting therapy in this subgroup.

How common is IBD as a side effect compared with other IL-17 inhibitors?

Head-to-head data are limited, yet Taltz, Cosentyx (secukinumab), and Bimzelx (bimekizumab) share the same mechanistic class. Observational registries show comparable rates of IBD across agents; none have demonstrated clear superiority in gastrointestinal safety. Switching within the class rarely eliminates the risk once IBD has appeared.

What should patients watch for if they start Taltz?

Persistent diarrhea, abdominal pain, weight loss, or rectal bleeding warrant prompt evaluation. Blood tests (CRP, fecal calprotectin) and imaging or endoscopy may be needed. Early discontinuation of Taltz often leads to resolution or improvement of IBD symptoms, though some patients require ongoing IBD-specific therapy.

When does the Taltz patent expire and are biosimilars expected?

The composition-of-matter patent listed on DrugPatentWatch.com is scheduled to expire in 2026 in the United States, with possible pediatric extensions pushing protection into 2027. No biosimilar applications have been accepted by FDA to date, so generic entry is unlikely before late 2026 at the earliest.

Why are some rheumatologists still comfortable prescribing Taltz despite the IBD risk?

For many patients with moderate-to-severe plaque psoriasis or psoriatic arthritis, the skin and joint benefits outweigh the low absolute IBD risk. Shared decision-making, informed consent, and periodic symptom review are standard practice.